Clinical Trial Update: Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck [Phase 2]

View source ↗

Summary

This Phase 2 trial update examines bortezomib followed by doxorubicin at progression in patients with locally advanced, recurrent, or metastatic adenoid cystic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma
• Oral Cavity Cancer
• Salivary Gland Cancer

Drugs mentioned

• Adriamycin (doxorubicin)
• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer | Phase 2 | Status: COMPLETED